Compare W & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | W | KRYS |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 10.3B |
| IPO Year | 2014 | 2017 |
| Metric | W | KRYS |
|---|---|---|
| Price | $92.82 | $370.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 11 |
| Target Price | $105.82 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 3.4M | 332.7K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.15 | ★ 128.00 |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $7.39 | $38.74 |
| Revenue Next Year | $6.00 | $32.53 |
| P/E Ratio | ★ N/A | $204.75 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $53.13 | $130.50 |
| 52 Week High | $119.98 | $382.54 |
| Indicator | W | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 63.99 | 69.81 |
| Support Level | $80.08 | $244.43 |
| Resistance Level | $108.31 | N/A |
| Average True Range (ATR) | 4.90 | 13.20 |
| MACD | 0.24 | 1.53 |
| Stochastic Oscillator | 73.30 | 80.21 |
Wayfair engages in e-commerce in the United States (88% of 2025 sales), Canada, the United Kingdom, and Ireland. It's also embarked on expansion into the brick-and-mortar landscape, with 13 stores (excluding outlets) between the AllModern, Birch Lane, Joss & Main, and Wayfair banners. At the end of 2025, the firm offered more than 40 million products from more than 20,000 suppliers under the brands Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold. Its offerings include furniture, everyday and seasonal decor, decorative accents, housewares, as well as advertising and logistics services. Wayfair was founded in 2002 and began trading publicly in 2014.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.